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ABSTRACT 
Objective: The objective of the present work was to conduct accelerated stability study as per international council for harmonisation (ICH) 
guidelines and to establish shelf life of controlled release dosage form of ropinirole hydrochloride and pramipexole dihydrochloride microspheres 
for a period of 6 mo. 
Methods: Most optimized batch of ropinirole hydrochloride and pramipexole dihydrochloride (F12 and M12 respectively) were selected and 
subjected to exhaustive stability testing by keeping the sample in stability oven for a period of 3 and 6 mo. Various parameters like surface 
morphology, particle size, drug content, in vitro drug release and shelf life were evaluated at 3 and 6 mo period. The surface morphology of the 
formulated microspheres was determined by scanning electron microscopy (SEM). The particle size of the microspheres was estimated by optical 
microscopy method. The drug content was assayed by the help of ultra-violet spectrophotometer (UV). The in vitro drug release was performed by 
using Paddle II type dissolution apparatus and the filtrate was analyzed by UV spectrophotometer. The shelf life of the optimized microspheres was 
calculated by using the rate constant value of the zero-order reaction. 
Results: A minor change was recorded in average particle size of F12 and M12 microspheres after storage for 6 mo. For F12 and M12, initially the 
particle size was 130.00 µm and 128.92 µm respectively and after 6 mo it was found to be 130.92 µm and 128.99 µm respectively. There was no 
change in surface morphology of F12 and M12 microspheres after 6 mo of storage. The shape of microspheres remained spherical and smooth after 
6 mo. An insignificant difference of drug content was recorded after 6 mo compared to the freshly prepared formulation. For F12 and M12, 94.50% 
and 93.77% of the drug was present initially and after 6 mo 94.45% and 93.72% of the drug was recorded. In vitro drug release was recorded after 
6 mo for F12 and M12. Initially, 97.99% and 97.69% of the drug was released till 14th hour respectively for F12 and M12. After 6 mo, 98.23% and 
97.99% of the drug was released respectively. The percentage residual drug content revealed that the degradation of microspheres was low. 
Considering the initial percentage residual drug content as 100%, 99.94% of the drug was recorded for both F12 and M12. The shelf life for F12 and 
M12 was found to be 10 y 52 d and 10 y 70 d respectively which were determined by the zero-order kinetic equation. 
Conclusion: A more or less similar surface morphology, particle size, drug content and percent of drug release before and after stability study 
confirmed the stability of F12 and M12 microspheres after storage for 6 mo and prove the efficacy of the microspheres in the site-specific delivery 
of drugs in Parkinson’s disease. 
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Drug development process plays an important role in achieving 
scientific success and commercial launching of the drug product. The 
study of storage stability is of important concern in the development 
of a pharmaceutical product. During the developmental stage, 
pharmaceutical analysis and stability studies are the most important 
steps required to determine and assure the identity, potency, and 
purity of ingredients, as well as formulated products [1, 2]. 
Stability of a pharmaceutical product is defined as the capacity of a 
particular formulation in a specific condition or in a specific 
container to maintain its physical, chemical, microbiological, 
therapeutical and toxicological specifications. Various chemical, 
physical and microbiological reactions may change the original 
properties of a preparation during transport, storage, and use [1, 2]. 
A stable drug delivery system should not only maintain its integrity 
and morphology but also the nature of the entrapped drug, 
percentage drug content and in vitro drug release rate [1, 2].  
Drug formulation’s stability testing is a complex process involving a 
variety of factors during which it may undergo a change in 
appearance, consistency, content uniformity, particle size and shape, 
moisture contents, pH and package integrity thereby affecting its 
stability. Various chemical reactions may occur in the 
pharmaceutical product such as reduction, oxidation, and 
racemization and may lead to the formation of the degradation 
product, loss of excipients and active pharmaceutical ingredient 
(API) potency, loss of activity etc [1, 2]. 
Stability studies ensuring the maintenance of product quality, safety 
and efficacy throughout the shelf life are considered a pre-requisite 
for the acceptance and approval of any pharmaceutical product. 
These studies are required to be conducted in a planned way 
following the guidelines issued by ICH (table 2) [1-3]. 
Ropinirole hydrochloride and pramipexole dihydrochloride are non-
ergoline dopamine D2 receptor agonist used in the treatment of 
Parkinson's disease. Both the drugs undergo an extensive 
biotransformation, mainly through cytochrome P-450 CYP3A. They 
suffer from poor bioavailability (~30% to 40%) owing to an 
important first pass metabolism. Controlled release microspheres 
have been known for increasing the therapeutic efficacy and 
enhancing the physical as well as chemical stability of many drugs 
[4, 5]. In vitro evaluation of the formulation has been extensively 
studied.  
The rationale of the present investigation was to assess the stability 
profile of optimized formulation of ropinirole hydrochloride and 
pramipexole dihydrochloride (F12 and M12) using various 
combinations of eudragit RS100, eudragit RL100 and ethylcellulose 
at accelerated condition. In vitro characterization results showed 
prolonged and controlled drug release from spherical and highly 
entrapped microspheres. Now, during stability studies, extensive 
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work on particle size, SEM, percentage drug content, in vitro drug 
release and percentage residual content of the formulations at 
accelerated conditions was conducted. 
MATERIALS AND METHODS 
Materials 
Ropinirole hydrochloride was a gift sample provided by Central 
Drug Laboratory, Kolkata and pramipexole dihydrochloride was 
purchased from Sigma Aldrich. Eudragit RS 100 and eudragit RL 100 
were purchased from Yarrow chem product, Mumbai. Ethylcellulose 
and magnesium stearate was purchased from Loba Chemie, Mumbai. 
Span 80 was purchased from Merck specialties Private Limited. The 
stability study was carried out in stability chamber (Thermo Lab, 
Mumbai). The pure dug was of standard quality complying with 
official monographs. All the chemicals used for the analysis were of 
analytical grade complying with the official monograph. 
Formulation of ropinirole hydrochloride and pramipexole 
dihydrochloride microspheres 
Ropinirole hydrochloride and pramipexole dihydrochloride 
microspheres were prepared by solvent evaporation technique using a 
different amount of eudragit RS100, eudragit RL100 and ethylcellulose 
[6-8]. The formulation containing different drug: polymer ratios were 
coded as F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11 and F12 for 
ropinirole hydrochloride and M1, M2, M3, M4, M5, M6, M7, M8, M9, 
M10, M11 and M12 for pramipexole dihydrochloride. The composition 
of various formulations is mentioned in table 1. 
 
Table 1: Composition of ropinirole hydrochloride and pramipexole dihydrochloride microspheres 
Formulation 
code 




RS 100 and RL 
100 











       
F1 and M1 2 2 1:3 - - 50 
F2 and M2 2 2 1:4 - - 50 
F3 and M3 2 2 1:5 - - 50 
F4 and M4 2 2 1:6 - - 50 
F5 and M5 2 2 - 1:2.5:0.5 - 50 
F6 and M6 2 2 - 1:3:1 - 50 
F7 and M7 2 2 - 1:3.5:1.5 - 50 
F8 and M8 2 2 - 1:4:2 - 50 
F9 and M9 2 2 - - 1:2.5:0.5 50 
F10 and M10 2 2 - - 1:3:1 50 
F11 and M11 2 2 - - 1:3.5:1.5 50 
F12 and M12 2 2 - - 1:4:2 50 
F and M = formulation code 
 
Methods 
Accelerated stability study of ropinirole hydrochloride and 
pramipexole dihydrochloride microspheres 
The most optimized batch of ropinirole hydrochloride and 
pramipexole dihydrochloride (F12 and M12 respectively) were 
selected and subjected to exhaustive stability testing at 40°C± 2°C, 
75 % RH±5% RH for 6 mo using stability oven (Thermo Lab, 
Mumbai). Samples were withdrawn at 3 and 6 mo period 
according to ICH guidelines (table 3) [9, 10]. Various in vitro 
parameters and shelf life were evaluated [11, 12].  
Statistical evaluation was done using analysis of variance (ANOVA) 
at P≤0.05 significance level and it was found to be statistically 
significant with P value<0.05. 
 
Table 2: ICH guidelines for stability testing of new formulation 
Study Storage conditions Minimum time period covered by data at submission 
Long-term  25 °C±2 °C/60% RH (relative humidity)±5% RH or 30 °C±2 °C/65% 
RH±5% RH 
12 mo 
Intermediate  30 °C±2 °C/65% RH±5% RH 6 mo 
Accelerated  40 °C±2 °C/75% RH±5% RH 6 mo 
 
Microsphere particle size and structural integrity  
Selected formulations were stored in amber colored glass bottles at 
40 °C±2 °C, 75% RH±5% RH for a period of 6 mo and examined for 
any change in particle size and surface morphology. The particle size 
of the microspheres was determined by optical microscopy (Motic 
digital microscope, B1 Advanced series) [13]. The eyepiece 
micrometer was calibrated with the help of a stage micrometer. The 
particle diameter of more than 50 microspheres was measured 
randomly. The average particle size (table 3) was determined by 
using Edmondson’s equation [Mean Particle size = Ʃ (mean particle 
size of the fraction × weight fraction)/Ʃ (weight fraction)]. The 
surface morphology of the microspheres was determined by SEM 
analysis (JEOL MAKE UK; MODEL-JSM 6360). The samples for the 
SEM analysis were prepared by sprinkling the microspheres on one 
side of an adhesive stub. The microspheres were then coated with 
gold [13]. Finally, the microspheres were observed with scanning 
electron microscope (fig. 1). 
Drug content  
After 3 and 6 mo, the drug content of microspheres was 
determined by milling and immersing the microsphere in distilled 
water after which they were stirred for 4 h (hour) and left at room 
temperature overnight. Then it was filtered by using Whatmann 
filter paper after which the volume was made up by washing the 
residue and assayed in UV spectrophotometer (Shimadzu-1700, 
Japan) [14, 15].  
The absorbance was determined at λmax against blank. The quantity 
of ropinirole hydrochloride and pramipexole dihydrochloride 
microencapsulated was calculated from the standard calibration 
curve of the drug (table 4). 
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In vitro drug release studies after storage at accelerated term 
temperature  
In vitro release studies were performed by using USP II dissolution 
(Paddle type). An accurately weighed sample (75 mg) of 
microspheres was suspended into 900 ml of phosphate buffer (pH 
7.4) maintained at a temperature of 37 °C±0.5 °C and stirred at a 
speed of 100 rpm (round per minute). At predetermined time 
intervals, a 5 ml aliquot of the sample was withdrawn and the 
volume was replaced with an equivalent amount of plain dissolution 
medium kept at 37 °C. The collected samples were filtered and 
analyzed at λmax using a UV spectrophotometer (Shimadzu-1700, 
Japan) against buffers taken as blank [16, 17]. Percentage drug 
released at different time intervals were calculated using Lambert-
Beer’s equation and shown in fig. 2 and fig. 3. 
Percentage residual drug content and estimation of shelf life  
Microspheres of each drug (200 mg) were milled and immersed 
in distilled water after which they were stirred for 4 h and left at 
room temperature overnight and then filtered with Whatmann 
filter paper and an aliquot of the filtrate was diluted with 
distilled water. The filtrate was analyzed for drug content and 
absorbance was measured using UV spectrophotometer 
(Shimadzu-1700, Japan) at different nano-meter specific to drugs 
[18, 19]. The percentage residual content was calculated and 
reported in table 5. The degradation rate constant and shelf life 
(table 6) of those samples were calculated using the following 
formula since the drug was released following zero-order 
kinetics [18, 19]. 
Shelflife  = K
C01.0
, where K = t
CC t−0
 
Where K  = Degradation rate constant, t  = Time in days, 0C  = 
Initial amount of drug and  
tC = Concentration of drug after time t (or final amount) 
RESULTS AND DISCUSSION 
Microsphere structural integrity and particle size 
A minor change was recorded in particle size of microspheres after 
storage for 3 and 6 mo. A linear relationship exists between the rate 
of degradation and particle size. In this study, the minor changes 
were noticed due to the humidity accelerating the aggregation of the 
microspheres and the evaporation of residual amount of organic 
solvent but the change was minimal since a constant temperature 
was maintained throughout the study. According to a previous 
study, temperature played an important role in maintaining the size 
of the particles. It was reported that the microspheres remained 
intact even after three years but as the temperature was increased, 
the rate of degradation also increased and hence the particle size 
was affected [20]. The shape of microspheres was examined by SEM 
which was initially spherical and smooth but there was no change in 
surface morphology after 6 mo of storage in case of formulations 
F12 and M12. The structural integrity was maintained even after six 
months because the polymer maintained its crystallinity. This was 
possible because the polymers used in this study do not have a very 
high molecular weight. In a previous study, it was seen that polymer 
molecular weight not only translates to longer degradation times but 
also to a change in polymer properties [21, 22] 
Drug content 
On analysis of drug content of microspheres, insignificant 
differences were recorded after 3 and 6 mo in comparison to the 
freshly prepared formulations. This non-significant loss was due to a 
slight loss of integrity of the system. According to a previous paper, 
it was reported that the microspheres prepared by solvent 
evaporation technique did not show any change in drug content 
even after three-year storage under desiccated condition [23]. 
 
Table 3: Particle size after storage at different time intervals 
Formulation code Parameters Observation on storage for 
Initial 3 mo 6 mo 
F12 Particle size 130.00±4.16 130.87±0.59 130.92±0.29 
M12 128.92±3.00 128.95±1.25 128.99±0.99 
(mean±SD; n=3), n = no. of observation, F and M = formulation code 
 
 
Fig. 1: Surface morphology of F12 and M12 after 6 mo 
 
Table 4: Percentage drug content after storage at different time intervals 
Formulation code Parameters Observation on storage for 
Initial 3 mo 6 mo 
F12 Drug content 94.50±0.56 94.48±0.48 94.45±0.43 
M12 93.77±1.13 93.75±1.48 93.72±1.23 
(mean±SD; n=3), n = no. of observation, F and M = formulation code 
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In vitro drug release studies after storage at accelerated term 
temperature 
In vitro release study of the freshly prepared optimized formulations 
(F12 and M12) at pH 7.4 revealed that 97.99% and 97.69% of the 
drug was released till 14th hour respectively. After 3 mo, 98.01% 
and 97.82% of the drug was released till 14th hour respectively and 
after 6 mo 98.23% and 97.99% of the drug was released 
respectively. Thus, the difference in drug release after storage for 3 
and 6 mo was insignificant. The drug release was slightly increased 
due to the formation of more pores in the microspheres, allowing the 
release of more drugs through the pores. This occurred because of 
the evaporation of residual amount of solvent. The rate of 
evaporation is directly dependent on the temperature. As a result, if 
the temperature increases then the drug release may increase due to 
faster evaporation rate. According to a previous report, under 
prolonged storage, temperature becomes a dominant factor causing 
an increase in drug release [24]. 
 
 
Fig. 2: Percentage cumulative drug release after 6 mo storage of F12 for 14 h. All values are represented as mean±SD (n = 3) 
 
 
Fig. 3: Percentage cumulative drug release after 6 mo storage of M12 for 14 h. All values are represented as mean±SD (n = 3) 
 
Percentage residual drug content and shelf life 
The chemical stability study of the microspheres was carried out at 
accelerated temperatures. The percentage residual drug content was 
evaluated as a part of storage stability studies considering initial 
drug content as 100%. The thermal degradation of F12 and M12 
were studied by keeping the formulations at accelerated 
temperatures of 40 °C±2 °C/75% RH±5% RH. The degradation of 
microspheres was relatively very low at room temperature. Since 
the study was carried out at accelerated room temperature; the 
degradation in percentage residual content was low. According to a 
previous study, it was reported that temperature is directly 
proportional to the rate of degradation. So as the temperature was 
increased, the rate of degradation was also increased leading to the 
loss of active ingredients [25]. The shelf life of F12 and M12 was 
found to be 10 y 52 d and 10 y 70 d respectively. In this study, the 
shelf life was estimated to define the time up to which the product 
will remain stable under accelerated storage conditions. If the 
formulated product is not stored in accordance, then it would lead to 
degradation. In a previous study, it was reported that for new drugs 
it is a general practice to grant only two-year expiry initially for a 
six-month accelerated study and the shelf life for later years would 
be allowed only on production of real-time data for the subsequent 
years [26]. 
 
Table 5: Percentage residual drug content from optimized formulations on storage at an accelerated temperature 
Formulation code % Residual drug content on storage at accelerated temperature 
Initial 3 mo 6 mo 
    
F12 100 99.98±0.85 99.94±1.70 
M12 100 99.97±0.39 99.94±0.42 
(mean±SD; n=3), n = no. of observation, F and M = formulation code 
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Table 6: Shelf life of the optimized formulations after storage at an accelerated temperature 
S. No. Formulation code Value of k Value of t90% (d) Shelf life in y 
1 F12 0.00273 3841.46 10 y 52 d 
2 M12 0.00240 3907.08 10 y 70 d 
F and M = formulation code, k = zero-order rate constant, t90% = shelf life 
 
CONCLUSION 
Once the delivery system is developed, the practical utility of the 
formulation depends on the maintenance of the therapeutic efficacy 
throughout the shelf life under different storage conditions. Prediction 
of stability of a dosage form is necessary due to legal, moral, economic, 
competitive and public health reason. Various in vitro characterization 
parameters of the microsphere was assessed after storage of the 
formulation for 3 and 6 mo at 40 °C±2 °C/75% RH±5% RH according 
to ICH guidelines and results were compared with those obtained 
before storage. A minor change was recorded in average particle size 
of F12 and M12 microspheres after storage for 3 and 6 mo. The shape 
of F12 and M12 microspheres were examined by SEM and there was 
no change in surface morphology after 3 and 6 mo of storage. On 
analysis of drug content of F12 and M12 microspheres, insignificant 
differences were recorded after 3 and 6 mo in comparison to the 
freshly prepared formulation. The difference in drug release after 
storage for 3 and 6 mo was insignificant. A more or less similar percent 
of drug release before and after stability study confirmed the stability 
of F12 and M12 microspheres after storage for 6 mo and proves the 
efficacy of the microspheres in the site-specific delivery of drugs in 
Parkinson’s disease. The percentage residual drug content revealed 
that the degradation of microspheres was relatively very low and the 
shelf life for F12 and M12 was found to be 10 y 52 d and 10 y 70 d 
respectively. 
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